Screenshot: healthcare-in-europe.com

Algorithmic tool

Google screens for depression - is that really a good thing?

With one in five Americans experiencing clinical depression in their lifetime, should Google offer an online screening test for depression? US based clinical psychiatrist Ken Duckworth says providing a screening test to people who are already seeking information online “could raise awareness to improve identification and treatment.”

A Google search for “Am I depressed?” (or similar) via mobile phone will offer a link to the patient health questionnaire (PHQ-9) test - a screening tool used by doctors to monitor the severity of depression and response to treatment. Links to materials from the National Alliance on Mental Illness (NAMI) and telephone helplines will be offered with test results for people with higher scores. He points out that this is not meant to replace clinical screening, nor does it constitute a universal screening program. Instead, “it is intended to prompt informed conversations with clinical professionals and to suggest potentially helpful resources.”

And he stresses that the result alone cannot drive treatment without a professional making a formal diagnosis. Nor should it threaten privacy, as Google will not store or log any responses or results, or link these with individuals’ other data. “Increasing the motivated public’s understanding of this validated screening tool could help to empower patients,” he writes. “Informed people may have a better chance of getting the help they may need.”

Google’s initiative has been reported positively and uncritically despite bypassing the usual checks and balances that exist for good reason

Simon Gilbody

But Simon Gilbody, a clinician and professor of psychological medicine at the University of York UK, believes that unregulated screening for depression will be ineffective and worries if could cause harm. He raises concerns over inadequate treatment resources to meet demand and assurances about privacy and misuse of data. “There are reasons to be concerned that data generated by a depression screening programme might be used to market antidepressants,” he says. 

He argues that depression should be diagnosed following a clinical assessment rather than a one-time screening test, warning that “episodes of transient (and self limiting) psychological distress will be confused with pervasive disorders that warrant treatment.” And he points out that recent disease awareness campaigns and unregulated screening programmes “present risks of overdiagnosis, supplier induced demand, and inappropriate treatment.” “Google’s initiative has been reported positively and uncritically despite bypassing the usual checks and balances that exist for good reason. It is unlikely that their initiative will improve population health and may in fact do harm,” he concludes.


In a linked commentary, mental health services user David Gilbert argues that by offering the PHQ-9 test online, Google is entrenching outdated ways of thinking about mental health.

This diagnostic tool focuses on physiological and biomedical symptoms, he writes. It puts firm emphasis on dysfunction and frames distress from the outset as an illness. He points to other ways to make a more meaningful diagnosis, but asks how much room might there be for this sort of dialogue if Google’s approach spreads? There is hope, he says, but change will happen only if service users have power and are equal partners with corporations like Google, so that decisions are made together. “Only then will online tools be a key that unlocks sense making, choice, and control.”


Source: The BMJ

14.09.2017

Related articles

AI in hospitals

‘Radiologists are about to disappear’

San Carlos Hospital in Madrid has undertaken a number of projects to promote artificial intelligence (AI) use in clinical practice. Dr Julio Mayol, Medical Director and Head of the Innovation Unit,…

Tomosynthesis

Ready to take over?

Results from recent trials are promising: an almost 40% increased breast cancer detection rate from digital breast tomosynthesis (DBT screening compared to conventional mammography.

App helps patients with depression

Approximately 16 million American adults are affected by depression. However, many patients see a psychiatrist only once every two to three months. Recognizing that patients often forget how their…

Related products

R/F Digital - Digital

Agfa - DR 600 (ceiling suspended)

Agfa HealthCare

R/F Digital - Digital

Agfa - DX-D 300

Agfa HealthCare

R/F Digital - Digital

Agfa - DX-D 40 detector

Agfa HealthCare

Accessories / Complementary Systems

Agfa Enterprise Imaging Business Intelligence

Agfa HealthCare

Accessories / Complementary Systems

Agfa Enterprise Imaging Exchange

Agfa HealthCare